Observation on acupoint electric stimulation combined with tropisetron in preventing and treating nausea and vomiting and improving the patient's appetite after TACE for primary or metastatic liver cancer patients.

• Classification of nausea and vomiting, as measured by NCI CTC-AE version 3
• The improvement of appetite, as measure by the classification of Appetite in accordance with NCI CTC-AE version 3.
• Quality of life: use M. D. Anderson symptom scale (the m. d. Anderson Symptom Inventory,MDASI)

Inclusion Criteria:

• ECOG physical status 0,1,2
• would accept the transcatheter hepatic arterial chemoembolization of primary or metastatic liver cancer patients;
• Adult male and female 3, age 18 years old;
• the chem-scheme of arterial infusion chemotherapy based on oxaliplatin dosage of 200mg;
• signed the informed consent and understand the study design;
• Organ function examination in patients must meet the following laboratory indexes: Neutrophil>500/Ul, hemoglobin > 8 gm/dL, platelet >100000/uL,Creatinine < 2 mg/dL bilirubin < 1.5 mg/dL, , alanine aminotransferase < 3 times the normal value, albumin >30g/L
• understand and complete quality of life scale ;
• women of childbearing age urine pregnancy test was negative.

Exclusion Criteria:

• The combined use of other venous chemotherapy within 5 days after TACE;
• skin infection on or near the points;
• skin hyperalgesia, unable to withstand electrical stimulation;
• other confounding factors may cause nausea and vomiting (such as intestinal obstruction, anorexia, etc.);
• heart, cerebrovascular accident history or the history of spinal cord injury;
• intestinal obstruction lead to nausea and vomiting
• installing pacemaker;
• cognitive dysfunction, unable to finish Scale;
• currently using acupuncture therapy.